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Logistics of the Multiple Organ Donor 
Procurement 
INTRODUCTION 
During the past 30 years solid organ trans-
plantation (heart, lung, liver, kidney, pancreas and 
intestine) has become a successful and widelv ac-
cepted form of treatment for a variety of conditions. 
However, the shortage of cadaveric organs is hin-
dering the larger use of this therapeutic option. In 
spite of the progressive evolution of public and pro-
fessional understanding and acceptance of organ 
donation during the past 30 years, only a little over 
25% of all potential brain-dead organ donors will 
actually come to donation [1-3]. As of September 30, 
1993, there were 32,532 transplant candidates on 
the United Network for Organ Sharing (UN OS) 
waiting list [4], representing an increase of 338% 
from December, 1986 (9,632). At the same time, the 
supply of organ donors underwent a marginal in-
crease between 1986 and 1991 (from approximately 
4,000 to 4,500), and has been stable in the past 2 
years, with 4,534 in 1992 [5-7] (Fig. 4.1). It is also es-
timated that every day 7 potential organ recipients 
in the United States will die before a suitable organ 
is found [8]. Consequently, while the need has in-
creased dramatically, we observe with mounting 
concern the persistent wastage of available organs, 
and the death of potential recipients. These are 
both mainly related to unwillingness to donate, or a 
lack of awareness regarding donation, as well as de-
lays or failure by the medical staff to consider organ 
donation [3]. In addition, there are other forces at 
work that have significantly decreased organ avail-
ability for the sicker patients, such as a policy im-
plemented by UNOS in 1991 that substantially 
changed previous allocation criteria [9]. 
As a result of this, there is now an even more lim-
ited number of organs available for the most severely 
ill patients, and some advocate their outright exclu-
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Fig. 4.1. Organ donor supply in the United States. 1980 
through 1992 (from [19)). 
sion from transplant candidacy, in favor of the elec-
tive cases [10]. 
Many routes have been explored in an attempt to 
remedy this situation, including the development of 
artificial organs [11], utilization of living donors even 
for extra-renal organs [12, 13], xenotransplantation 
[14-17] (see also Chapter 22), and non-heartbeating 
donors [18]. 
However, a more immediate impact on organ 
shortage could be effected by improving our current 
mechanisms for organ recovery, and the manage-
ment of potential donors. 
In this chapter we will address the logistics of 
multiple organ procurement, as well as the clinical 
management of the multiple organ· donor, as cur-
rently practiced in the United States and, particular-
ly, at the Pittsburgh Transplantation Institute [19]. 
zz 
ORGAN RECOVERY 
Standardized criteria for the determination of 
brain death were defined b\' the Ad Hoc Committee 
of the Harvard Medical School [20], and have been 
the subject of a more recent report [21]. Todav the 
concept of brain death is widely accepted by the sci-
entific community, and once a potential brain dead 
organ donor is i~ientifiedI the multiple organ pro-
curement process should be triggered. This starts b\' 
contacting the local Orgcll1 Procurement Organiza-
tion (OrO) as soon clS the irreversibilit!, of brain in-
jur\' has been established. In 1992, there were 6S 
oros and 266 transplant centers in till' United 
States. These represent the largest organ procure-
ment and transplant network in the world. Most in-
tensive care units (lCU) have the telephone number 
of the local agency available. However, the phOIw 
number and location of the area's oro can be ob-
tained from the UNOS, who has a 24-hour phone 
line (800-243-6667). These oros, originally set up to 
organize the recoverv of kidne\'s, coordinate the 
co~11plex logistics of illultiple organ recovery, and 
their distribution \Yithin a predetermined geograph-
ical area. They are also responsible for the payment 
of all charges incurred during the process of organ 
donation, ensuring that donor families are not billed 
for anv of them. Once contacted, the local oro will 
send a procurement coordinator to the referring hos-
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pita!. These coordinators perform a number of ad-
ministrative and technical functions, c()\'ering ever\, 
aspect of the donation process. Upon receiving a re-
ferr,,1 they will perform an evaluation and discuss 
organ donation with the potenti,ll donor's famil\', 
making sure the relatives have a complete and satis-
facton' explanation of the diagnosis of brain death 
and a clear understanding llt the organ procurement 
process. . 
Families should be informed separateh', but Il~ 
soon as possible, "fter the irreversibility of the lethal 
brain damage has been established, and given a clear 
explanation of the prognosis. qhi~ will give them 
time to accept the patient's death, and allow them to 
deal with their grief. It is extremely important to rl'-
spect this phase, as it has been demonstrated thelt 
consent for donation increases from ISO" to 60':;, if 
the family is allowed to de,,1 with the concept of 
brain de,lth first, and the i~sue of organ don"tioll is 
brought up at a later time [3]. Religious beliefs about 
human life, the deild btkh, and life after death are 
extremely important considerations for those in-
volved in organ donation and transplantatilln. Nll 
major religion specifically prohibits organ donation, 
although in some situations there ma\' be restric-
tions. Table 4.1 summarizes some of tl1e major reli-
gious and cultural beliefs associated with organ dll-
;1ation and transplantation [22]. Families l~ay feel 
the need to discuss the matter with a church repre-
sentative before making a decision. 
Table 4.1. Major religious and cultural beliefs aSSOCiated with organ donation and transplantation (from [19]). 
Group 
Amish 
Baha'i 
Baptist 
Buddhist Church of America 
Christian Sciences 
Church of Jesus Christ of Latter Day 
Saints 
Episcopal Church 
Evangelical Covenant Church 
Greek Orthodox Church 
Gypsies 
Hinduism 
Islam 
Jehovah's Witness 
Judaism 
Protestant Denominations 
Religious Society of Friends (Quakers) 
Roman Catholic Church 
Unitarian Universalist 
United Methodist Church 
Donation 
Reluctant if transplant outcome un-
certain 
Acceptable 
Individual deciSion 
Individual decision 
Individual decision 
Individual decision 
Encouraged 
Encouraged 
Acceptable (although not for re-
search) 
Against 
Individual deciSion 
Acceptable (organs of Moslem donors 
must be trasplanted immediately. 
and not stored in organ banks) 
Individual decision (not encouraged) 
Encouraged 
Individual decision 
Individual decision 
Encouraged 
Acceptable 
Encouraged 
Transplantation 
Acceptable for the well-being of the 
candidate 
Acceptable 
Acceptable 
Buddha's teachings on the middle 
path (i.e. the avoidance of ex-
tremes) could be applicable to this 
Individual decision 
Individual decision 
Encouraged 
Encouraged 
Acceptable for the well-being of the 
candidate 
Against 
Individual decision 
Acceptable 
May be considered acceptable (orga-
ns should be completely drained 
of blood before transplantation) 
Encouraged 
Acceptable 
Individual decision 
Acceptable 
Acceptable 
Acceptable 
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If the fami1\' decides to donate, a "consent for do-
nation" form" is supplied by the hospital or by the 
procurement coordinator, and is completed and 
signed by the next-of-kin. In addition, the coor-
dinator sees to it that all medicolegal requirements 
are met, from adequate documentation of brain 
death in the chart to securing permission from the 
coroner when necessar~·K Medical staff privileges for 
the recovery teams are also arranged. Hospitals dif-
fer in their policies for granting such privileges. 
Some hospitals do not consider the organ procure-
ment as a surgical procedure, because a determina-
tion of brain death has already been made. In this 
circumstance, temporary privileges are not required 
for outside surgeons. 
At the same time the procurement coordinator as-
sumes control of three main activities: 
• donor evaluation; 
• donor management and coordination of donor 
and recipient matching; 
• donor operation, organ preservation, and ship-
ment to the recipient's hospitals. 
The role of the coordinator in each of these is crit-
icaL because the most important issue in organ pro-
curement, once the decision to proceed has been 
made, is to have someone who "directs traffic", 
maintaining clear lines of communication between 
the members of the difterent teams involved. A lack 
of communication at this point can disrupt donor 
care and compromise organ stability. Therefore, the 
needs and protocols of the individual teams should 
be discussed in detail before any donor surgery is 
begun. In addition, if at all possible, the logistic ar-
rangements between teams should be expedited so 
that no time constraints are placed on the host team. 
On the other hand, the host team must be tolerant, 
because different organs often have to be flown to 
distant parts of the country, and some recipient sur-
gery may be quite complex and time consuming. To 
facilitate matters the host team should make avail-
able basic information on the donor, to expedite the 
evaluation by the visiting teams (Fig. 4.2). 
MULTIPLE ORGAN DONOR EVALUATION 
There are verv few absolute contraindications to 
organ donation:and they can be grouped into three 
broad categories: 
• severe trauma; 
• malignancy outside of the Central Nervous Sys-
tem (CNS); 
• active infections. 
The first category, that of trauma, refers only to in-
jury to the organ itself, and will not preclude dona-
tion of those organs that are not affected. Malig-
nancy, other than primary CNS tumors, will also dis-
qualify the prospective donor. An important group 
of exclusionary criteria is the presence of active in-
/.R. Manno. H.R. Doyle. C. Scottl-Fog/leni. TE. Stan:1 
fections. Svstemic sepsis, active tuberculosis, viral 
encephalitis and Guillain-Barr svndrome are COI1-
traindications to org,1\1 donation; as well as active 
hepatitis, or the presence of the hepatitis B surface 
antigen. Past infection with hepatitis B virus, as evi-
denced bv the presence of antibodies, does not pre-
clude donation. Whether organs should be used if 
the donor has hepatitis C antibodies has been the 
subject of controversy in the last fev\, vears. There is 
evidence in the literature for HCV transmission after 
transplantation [23]. However, the donor shortage is 
so serious at this time that HCV positive donors 
need to be considered, at least for lite-saving organs 
like liver, heart and lungs [24]. Policies concerning 
other organs, like kidney and pancreas, are currently 
being debated [23, 25]. 
The human immunodeficiency virus (HIV) has 
had a great impact on the field 'of transplantation, 
and donors who test positive for HIV antibody are 
rejected. Prospective donors should also have a Ve-
nereal Disease Research Laboratorv test (VORL), as 
well as cytomegalovirus (CMV) tite'rs, determined as 
soon as possible. The significance of a positive VORL 
is difficult to ascertain, but it is our practice to treat 
recipients of VORL-positive donors with a course of 
benzathine penicillin. The CMV status of the donor 
has prognostic significance regarding the incidence, 
and severity, of subsequent CMV infections. Recip-
ients of organs harvested from seronegative donors 
have a lesser chance of developing a CMV infection, 
regardless of their own serologic status [26-28]. Ep-
stein-Barr (EBV) and Varicella Zoster virus (VZV) are 
not part of the usual viral screening. The only sit-
uation where these viruses become relevant is when 
the donor has active disease related to them (in-
fectious mononucleosis or svstemic VZV infection). 
If this is the case, organ donation should not be con-
sidered. 
Donors with infections under control, or those af-
fecting organs not specifically considered for dona-
tion (i.e. an abdominal organ donor suffering from 
pneumonia) may still be suitable. Children who die 
due to bacterial meningitis related to Hemophilus ill-
f1l1cnzac or Neisseria mellillgitidis can still be consid-
ered for donation, if the organism and its sensitivity 
are known beforehand. 
Prolonged organ ischemia related to severe hypo-
tension or cardiac arrest might represent a contrain-
dication to donation. However, it is the policy of the 
Pittsburgh Transplantation Institute to critically eval-
uate all donors, including those with cardiac arrest 
and prolonged CPR. In fact, many of these donors 
have been found acceptable by post-CPR physiolog-
ical and biochemical criteria, and their organs have 
been successfully transplanted [18, 29, 30]. 
Other patients that may not be acceptable as do-
nors are those with a long-standing history of dia-
betes mellitus, hypertension, cardiac or peripheral 
vascular disease. But, again, the donor and organ 
viability assessments should be carried out on a case 
by case basis, and a patient not acceptable as a heart 
or lung donor might still be an excellent abdominal 
organ donor. Sometimes the suitability of individual 
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Table 4.2. Age guidelines for organ and tissue donation 
used at the Pittsburgh Transplantation Institute (from 
[19]). 
OrganfTissue Age (year) 
Heart :!S60( ') 
Heart-lungs :!S60C) 
Lungs :!S60( ') 
Kidney 1 month-75C) 
Liver :!S75C) 
Pancreas :!S65C) 
Intestine(2) 
Bone 15-65 
Bone marrow :!S75 
Cornea 1-65 
Skm 15-65 
Heart valves :!S55 
(') Donors beyond these age limits could be accepted on the bases of the indi· 
vidual organ function. 
n No age limIts have been set for intestinal donors. Intestines should be avail-
able from most organ donors and are always evaluated on an mdividual 
bases. 
organs can be assessed only after direct examination 
by the donor surgeon, at the time of procurement. 
The donor age deserves special mention. The 
chronological age is less important than the physio-
logic age, .when assessing for specific organ dona-
t~or:Kc?r some organs age may not be an important 
lImiting factor PI]. The liver is, in a certain way, pro-
tect~d from agmg, and we have successfully used liv-
ers tromdonors as old as 75 years. Popper, in 1985, 
dedicated an extensive review to the aging of the liv-
e.r [32]. According to his study, the organ's great func-
tIonal reserve, its regenerative capacity, and its large 
blood supply are the key factors in delaying aging in 
the lIver, as compared to other organs. Table 4.2 
sho\·\,s. the. ag~ guidelines for individual organs used 
m our mstItutIon. In general it is rare to find a suitable 
heart or lu~g allogra~t f~om donors over the age of 60 
due to the mcreased mCldence of coronary artery dis-
ease and chrome pulmonary disease. 
In summary, given the enormous need for organs 
and the very few criteria that absolutely disqualify a 
potential donor, the local oro should be contacted 
in virtually every case. Figure 4.2 shows the data col-
lection form used by the Center for Organ Recovery 
and Education (CORE: the Western Pennsylvania 
Southern New York and West Virginia organ pro~ 
curement agen~yFK qhes~ data should be promptly 
faxed to those mvolved m the evaluation process. 
INDIVIDUAL ORGAN ASSESSMENT: 
ABDOMINAL ORGANS 
The criteria used to determine the suitability of 
kidneys are very flexible. As shown in Table 4:2, a 
kidney donor can be between 1 month and 75 years 
of age. Serum creatinine and blood urea nitrogen' 
(BUN) are used as markers of donor renal function, 
and should be normal. Obviously, donors with 
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chronic renal disease are not considered tor kidney 
donation. However, patients with transient cre-
atinine and BUN elevations, related to delwdration 
and/or hypotension, are not excluded from kidne\' 
donation if the BUN and creatinine fall after appn)-
priate volume correction. 
Attempts at predicting liver allograft function fol-
lowing transplantation, based upon donor informa-
tion, have met with little success. The diverse litera-
ture [24, 33-44J devoted to the topic is testimony to 
our lack of a clear understanding, one that can trims-
late into well-informed decision makin o during do-
nor evaluation. As a rule, the donor ~hould have 
normal or near-normal serum aspartate aminotrans-
terase (AST), serum alanine aminotransferase (ALT), 
bilirubin, and prothrombin time, but we have suc-
cessfully used livers from donors with AST and ALT 
that were 15 times over the upper limit of normal. 
The Important parameter is not an isolated AST and/ 
or ALT value, but the trend established since the 
rcu admission [45]. The bilirubin can be elevated 
due to m~ssive blood transfusions used during the 
r~~usCltation of a shocked patient. A history of hepa-
titis or alcoholIsm IS certainly a warning sign, but 
does not preclude the use of the liver. In general, in 
the case ot a marginal liver donor, the intraoperative 
assessm~ntK by the donor surgeon is the best single 
piece of mtormation. 
There is only one absolute exclusion criterion in 
the evaluation of a pancreas donor, and that is a his-
tory of diabetes mellitus. Amylase elevations have 
b~en seen in as many as 39% of pancreas donors, 
Without any evidence of pancreatitis, and thus iso-
lated hyperamylasemia does not contraindicate the 
use of the pancreas [46 J. The serum glucose mav be 
falsely elevated in donors receiving steroid therapy, 
or as a :esult of decreased circulating insulin [47]. 
fntestm~l transplantation is emerging as a valua-
ble Kmodal~ty for the treatment of patients with in-
testmal failure. Early in 1993 UNOS formed a sub-
comm,ittee responsible for systematizing the listing 
of reCIpients, help identifv suitable donors and es-
tablish guidelines for the' equitable allocati~n of in-
testmal grafts, both at the local and national levels. 
Because of the time constraints, it is impossible to 
perform a functional assessment of the donor bowel 
Relatively young age, hemodynamic stability, and 
donor-reciF:ient size match are the critical param-
eter~ us~d I.n evaluating an intestinal donor [48]. At 
our mstf~utfon: preference was initially given to in-
fant and Juvemle donors with stable hemodynamics. 
Howeve:, the age range has been gradually~ expand-
ed, prOVided the donor is stable and receiving mini-
m~l vasopressor ~up~ort (::::;10 J:lg/kg/min of dopa-
mm~FK SIze matchmg IS always given special consid-
~rationK The majority of intestinal transplant recip-
Ients have undergone extensive intestinal resections 
leading to a significant reduction in the size of th~ 
abdominal cavity. Therefore, donors are chosen that 
are 15% to ~l% smaller in body weight than the se-
lected ~eclpl~nts [48]. The details of the management 
of the mtestmal donor are discussed extensively in 
Chapter 24. -
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INDIVIDUAL ORGAN ASSESSMENT: 
THORACIC ORGANS 
Besides a negati\'e history of cardiac disease and il 
normal chest X-ra\·. the d0l10r should hil\'e a normill 
heMt plwsical ex,im and 12-lead electrocilrdiogram. 
However, a number of electrocardiographic changes 
might be detected in brain dead patients, which do 
not preclude thoracic organ d(miltion [4Y, 50]. A 
brain dead patient able to maintain a systolic blood 
pressure greater than YO mmHg with a dopamine re-
quirement less thiln 10 .1Ig/kg/min is considered ,1 
suitable candidilte for l1eilrt donation [51. 521. Car-
diac isoenzvmes ilre recommended in case of chest 
trauma, to rule out myocardial contusion, ilnd when 
the potential donor 11as suffered a cardiac arrest or 
prolonged h~-potensionK The incidence of coronary 
ilrter\' disease c1earlv increases in male donors over 
the ~ge of 35, especii'lily in the face of risk factors 
sllch as hypercholesterolemia, familv history and " 
histor~: of smoking. Coronary angiographv may be 
helpful in the e\'aluation of high risk and older do-
nors, but it is not routinel:-' required, and most hos-
pitals wili find the logistics of performing it prohib-
itive. Therefore, a decision wili have to be made 
based on a c<trdiologic consultation, evaluating the 
history, electrocardiogram, and echocardiogram. As 
is the case for the liver, and due to the severe short-
age, it is prudent even in high risk donors to have 
the heart examined on the table following sternoto-
my. Visualizing and palpating the coronary arteries 
will give a significant amount of information with re-
spect to the incidence of coronary artery disease. jf 
plaques are felt along the left main coronary artery 
or left anterior descending artery, the heart, in most 
cases, will not be suitable for transplantation. In ex-
treme cases of a \'en' sick recipient, however, the 
transplant team may make a decision to take this 
heart, and isolated cases of coronary artery bypass 
being performed at the time of transplantation have 
been reported. Indeed, reports exist stating that in 
cases of isolated mild coronary artery disease, the 
donor allograft functions well with no increase in 
early mortality. 
Transesophageal echo cardiography has recently 
been demonstrated to be an important adjuvant in 
the evaluation of a potential cardiac donor. Severe 
cardiac hypertrophy, valvular defects and global 
myocardial dysfunction or segmental wall abnormal-
ities have been diagnosed in what appeared to be 
otherwise reasonable cardiac donors. At this time, 
limited information is available about the use of such 
hearts, and in most cases it will be prudent to ayoid 
the use of a heart with demonstrated wall motion ab-
normalities [53]. In general, minor changes in the 
electrocardiogram or echocardiogram, localized in-
fection [54], transitory hypotension, brief cardiac ar-
rest and thoracic trauma, do not contraindicate heart 
donation. The importance of donor-recipient weight 
mismatch over 20% is critical only in the face of high 
pulmonary vascular resistance. In carefully selected 
donors, survival following transplantation with a do-
nor between 40-55 years of age is no different than 
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that observed in the case of younger donors [551. A~ 
the limits for donor selection are extended, evidence 
becomes more clear that it is safe to extend donor 
age up to 55-60, and ischemic time farther than four 
to five hours [56-58]. 
All of the selection criteria mentioned in the case 
of a heart donor also apply to heart-lung or isolated 
single or double lung donors. In addition, a donor is 
not acceptable for lung or heart-lung donation when 
there is a history of heavv smoking, chronic lung 
disease, or pulmonary aspiration. The height. weight 
and chest circumference of the heart-lung donor 
should closeh- match those of the recipient. A num-
ber of physiological parameters can be used when 
assessing a lung donor, including the PaO/FlOc ratio 
E~OREl torr) and peak airway pressure «30 cm HcO 
with 15 mLlkg of tidal volume and 5 em H20 of 
PEEP) [59-61]. 
Aspiration pneumonia is frequent in the brain 
dead patient. and thus the character of the sputum 
is a critical piece of intormation. The role of bron-
choscopy is still being debated, considered mand,l-
tory bv some authors [62], while others feel it is in-
dicated only v,hen there is a question of foreign-
body aspiration, or to obtain sputum for Gram stain 
and culture [47]. 
Bronchoscopy will provide, however, important 
culture information to guide appropriate antibiotic 
therapy following transplantation. In cases where 
frank purulence is noted on bronchoscopy, the lungs 
will not be suitable. However, it is conceivable that 
one lung may be salvaged for transplantation from a 
set where one appears to be more infected than the 
other. 
MULTIPLE ORGAN DONOR MANAGEMENT 
Once the coordinator finishes the donor eval-
uation there are still man V hours of intense work be-
fore completing the process. After obtaining the ap-
propriate consent, therapeutic efforts should be 
geared to protect the donated organs, until the ac-
tual retrieval can be carried out. 
While in the '70s and early '80s donor manage-
ment mainly, if not exclusively, addressed kidney 
function, nowadays the patient must always be ap-
proached as a multiorgan donor, and this can pre-
sent a real challenge to the physician managing the 
case. He or she should keep the patient hemody-
namically stable, with optimal organ perfusion and 
oxygenation. This is not easy due to the loss of many 
body reflexes, and the dramatic changes in the hor-
monal milieu [63]. Several studies have shown a sig-
nificant reduction of cortisol [64], insulin [64J, and 
thvroid hormones [49, 64-68]. Also, 50-70% of brain-
dead patients suffer from diabetes insipidus [69, 70). 
A number of protocols that call for the use of hor-
mones like triiodothvronine, cortisol, or insulin dur-
ing donor management [47, 50, 65, 67, 68, 71] have 
given conflicting results. 
----..•... --... 
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HEMODYNAMIC MANAGEMENT 
Arterial line, centr,11 venous line, clnd a bladder 
catheter are mandaton' in the management of c1 
brain dead donor, while ,1 pulmonary arten' catheter 
is optional. The rostral tn caud,,1 brain function loss 
following brainstem herniation, vvith the destruction 
of pontil\e and medullary vasomotor centers, causes 
the development of significant hemodvnamic in-
stabilit\'. Before herni,ltion, Cushing's reflex can in-
duce b-radvarrl1\'thmias and hypertension. If brad\'-
cardia needs tt) be tre,lted, isoproterenol or epine-
phrine are the drugs of choice, since atropine is in-
effective because it acts on the brain's vagal output. 
Hypertension, related to increased sympathetic ac-
tivitv, can result in cardiac microintarcts and neuro-
genic pulmonarv edema. Therefore, it must i,lwavs 
be aggressivelv treated, to prevent damage to the 
thordcic organs. Beta-blockers have been shown to 
suppress the hypertension related to brain hernia-. 
tion in baboons, and esmolol is possibly the drug ot 
choice in this clinical setting because of its short half-
life. Ldter, when brain stem herniation results in the 
complete destruction of the pontine and medulian' 
vasomotor centers, hypotension becomes the main 
hemodvnamic problem, and 10-25% of brain dead 
donors sustain a cardiac arrest [47, 6Sl, 72J. 
The main goal of this phase of their management 
is to maintain a satisfactory organ perfusion, and eve-
ry attempt should be made to maintain a systolic 
blood pressure greater than liD mmHg, which is con-
sidered critical to preserve good kidney and liver 
function [73-76J. It has been reported that a mean ar-
terial pressure of 40 mmHg can still result in ade-
quate cardiac preservation in the pig [77J, and this 
information may be useful when trving to decide 
whether to use the heart of a hypotensive donor. 
However, the liver and the kidnev do not tolerate 
such low perfusion pressures if tl1ey are sustained. 
The large majority of these patients are cared for us-
ing head trauma protocols and, consequently, they 
are dehydrated by the time they have progressed to 
brain death. Usuallv, many liters of crystalloid are 
needed to achieve a'dequate filling pressures and al-
low weaning of the vasopressors, if thev are being 
used. Dopamine is the first choice among vaso-
pressor drugs, because of its ability to maintain good 
renal and splanchnic blood flow when used at low 
doses, Dopamine doses greater than 10 'Ig/kg/min 
should not be necessary if good filling pressures 
have been achieved with fluid replacement, and the 
use of drugs such as phenylephrine hydrochloride 
or norepinephrine bitartrate should be avoided, in 
order to protect organ perfusion [78]. These drugs al-
so increase myocardial oxygen consumption, and a 
correlation has been found between the use of cate-
cholamines, including dopamine, and poorer renal 
allograft survival [79). Dobutamine is a good choice 
in case an inotrope is needed. Other agents, such as 
isoproterenol, increase myocardial oxygen consump-
tion more significantly than dobutamine. 
We mentioned above that, in many cases, several 
liters of fluid are necessary to obtain good filling 
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pressures and, consequentl\', assure adequate org<1n 
perfusion with minimal use of vc1sopressors. In gen-
eral. we favor the use of crvstalloids o\'er th,lt of 
colloids because (If the cost, ~nd the f,lCt that there 
are no therapeutic advdntclges of one over the other. 
We use Ringer's lactate because tIll' brain dead do-
nor often presents with hypernatremia [-17J. Blood 
products such as fresh frozen plasma, platelets, and 
cryoprecipitate m,1\' be llsed if ,1 serious bleeding 
diathesis is present. Many brain dead donors h<1\'e ,1 
coagulopathv related t(l release of plasminogen ,1cti-
vator bv the injured cerebrill tissue into the s~Dstel1l­
ic circuh1tion. In these cases, I-'-amillllcaproic acid 
should be avoided because it can inducL' micro-
vascular thromboses in the donor orgcl11s. As in oth-
er areas of medicine, there is \1(1 clear evidence re-
garding the ideal hematocrit in the multiorgan do-
nor, although it has been suggested that it be kept 
between 25 and 35 [78, 80). 
The fact that 50-7U'!o of brain dead donors sutter 
from diabetes insipidus makes the maintenance of 
the intravc1scu lar volume a real challenge [781. Did-
betes insipidus, in this setting, is the result of dam-
age to the hvpEFthalamic-pituitar~D axis, with its ,)C-
companying decrease of antidiuretic hormone levels. 
The urine volume can easilv reach 15-2 Uhr, and 
this should be completely - replaced with a Inw-
sodium solution. Desmopressin (a synthetic ana-
logue of arginine vasopressin) is the drug of choice 
to treat diabetes insipidus in the brain dead donor, 
and it is usually administered in IV boluses of 0.5-2 
.1Ig every 8-12 hours. The dose is titrated in order to 
obtain a urinary volume of 100-250 mUhr. An output 
below 100 mUhr is not desirable because it has been 
shown to adversel\' affect kidnev function after the 
transplant [73]. Desmopressin is preferred to other 
drugs due to its minor vasoconstrictive effects, when 
compared to other vasopressin preparations, which 
appears to be of some importance in the final out-
come of the transplanted kidneys and livers [79, 81]. 
RESPIRATORY MANAGEMENT 
Mechanical ventilatory support is obviously re-
quired for all brain dead donors_ The management of 
the ventilator is the same as for other critically ill pa-
tients, and its principles will not be repeated here. 
Once again, treatment is aimed at ensuring that the 
prospective donor organs are maintained in the best 
possible state, and specific goals of ventilatory care 
are to maintain a PaO" between 70 and 100 mmHg, 
an oxygen saturation of arterial hemoglobin (SaO") 
greater than 95'10, and a PaCO" within the range of 
35 to 45 mmHg, to avoid pulmonary complications. 
High fractions of inspired oxygen should be avoided 
in lung and heart-lung donors to prevent oxygen 
toxicity and atelectasis. If an Fl02 greater than 0.60 is 
necessary to obtain a PaGe of at least 100 mmHg the 
lungs should be re-evaluated, to exclude any pathol-
ogy that might have been missed before. If any such 
pathology is now identified, and the lungs are no 
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longer acceptable for donation, higher levels of ox-
ygen are preferabl~K to a high PEEf',. since this can 
have deleterious eHects on the cardIac output and 
splanchnic perfusion. The decrease in brain metabo-
lism, tvpical of the brain dead patient, results in a re-
ductio-n of COe production, a11l~ thus minute ventila-
tion should be adjusted accordingly. 
COORDINATION OF DONOR 
AND RECIPIENT MATCHING 
During this phase the procurement coordinator 
asks local transplant programs about their needs tor 
organs. Under the current U.s. system local pro-
grams have first priority, and only when organs are 
not used locally' are inquiries made at the regional 
and national levels. An exception to this rule is when 
a prospective kidney recipient, who resides in an-
other region, is found to have a so-called "six anti-
gen match". These kidneys have to be sent away, 
with the receiving transplant center "paving back" at 
a later date. Organ allocation is a very complicated 
and controversial subject, and what svstem should 
be used is presently being debated [foJ. As of this 
writing, amendments to the National Organ Trans-
plant Act are being discussed in the Congress, and it 
is not clear what changes will be implemented. A 
point system for renal transplantation was devel-
oped in Pittsburgh in 1985, that gave credit points to 
renal transplant candidates. Credits were acquired 
for time waiting, quality of antigen match, degree of 
immunologic sensitization, medical urgency, and lo-
gistical considerations of getting the donor organ 
and the recipient together within the time limita-
tions of safe organ preservation. The system went 
in effect in western Pennsvlvania on Januarv 1, 1986 
[9J. Although initially adopted by UNOS· on No-
vember 1, 1987, the point system never went into 
effect at the national level due to difficulties en-
countered in reconciling it to a myriad of local in-
terests. A similar point system was developed for 
liver transplantation, having been in place at Pitts-
burgh since January, 1987. Our experience with or-
gan allocation based upon point systems, where or-
gans go to those who have been waiting longer or 
are sicker, has been most favorable. Graft and pa-
tient survivals have not suffered by giving organs to 
sicker or older patients. 
At the same time, our observations provide some 
assurance that the concepts of equitable access and 
efficient use of a scarce societal resource are not mu-
tuallv exclusive. 
HLA matching is not a critical issue for extrarenal 
organs. However, we routinely perform HLA typing 
on all extra-renal organs, a practice that is at variance 
with what most other institutions do in this country. 
Although it is expensive, we consider it important 
because it allows us to determine the presence of mi-
crochimerism in the recipient, information that may 
be extremely useful in the future, when deciding 
how to manage the immunosuppression [82J. 
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Whenever the recipients for all the abdominal 
and thoracic organs are identified, an operatin~ 
room time in the donor hospital is arranged. The 
procurement coordinator contacts the recipient in-
stitutions to arrange for the simultaneous arri\'al of 
'lll the harvesting teams. Kidneys have been pro-
cured by local teams for many years, and shipped if 
not used locall~·K Today, a similar practice is being 
adopted in the United States for other organs, par-
ticularlv livers [83J. 
The 'intestinal donor should receive intravenous 
ampicillin and cefotaxime, at the appropriate doses, 
when first evaluated, and even' 6 hours after that. 
The last dose is given in the operating room at the 
time of harvesting. Also, polv-ethvleneglycol-elec-
trolvte solution (Go/lltc/J/H) is administered through 
the "naso-gastric tube to' flush the intestine. The total 
amount ranges from 250-2,000 mL, depending on the 
recipient's bod\' size (250 mL in the infant - 2,000 mL 
in the adult) and the administration rate is 10-30 mLl 
min. After the intestinal flushing, an antibiotic mi>--
ture that includes polvmixin E (100 mg), tobramycin 
(80 mg), and amphotericin B (500 mg) is given 
through the naso-gastric tube every 4 hours, until 
procurement. In pediatric donors the doses are 
halved, while infants receive onlv one fourth of the 
dose. Newborns receive no intestinal preparation. If 
pre-harvest flushing cannot be performed this is 
done after procurelnent, using cold Ringer's lactate. 
Also, polymixin B or kanamycin can be substituted 
for polymixin E, if the latter is not available at the do-
nor hospital. 
MULTIPLE ORGAN DONOR OPERATION 
ANESTHESIA 
The donor operation can be time consuming and 
the role of the anesthesiologist is very important, es-
pecially if we compare the multiple organ procure-
ment that is now usually performed with those car-
ried out in the past, when the kidneys were often the 
only organs removed. A complete review of the an-
esthetic aspects of organ donation was recently pub-
lished [84], and we will restrict ourselves to its sa-
lient points. 
The goal of medical management during organ 
procurement is to avoid ischemic organ damage by 
optimizing organ perfusion. Therefore, care of the 
donor is a continuation of the intensive care that was 
provided before brain death. The most important is-
sue is the clear communication between the mem-
bers of the procurement team because the surgical 
procedure and procurement protocol may differ de-
pending on the procurement team and the specific 
organ. For the pre-operative evaluation of the donor 
the anesthesiologist should review the medical and 
surgical histories, including the cause of brain death, 
condition and supportive measures of vital organs, 
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drug allergies, and medications. Cardiopulmonar:-' 
function is assessed bv means of the hemodynamic 
profile, requirement o'f inotropic support, efticienc\' 
of gas exchange. degree of ventilator:-' support, chest 
X-ray, electrocardiogram, arterial blood gas tensions 
and 'acid-base state. Renal function is evaluated b\' 
urine output, blood urea nitrogen, and serum levels 
of creatinine and electrolvtes. Hepatic function is 
evaluated bv AST. ALl, and bilirubin, and pancreatic 
function bv blood glucose level and serum amvlase. 
Hemoglobin concentration and the blood type of the 
donor are identified to prepare blood products. In 
addition, the validity of brain death certification, 
consent from familv ;'1embers, and permission from 
the coroner are verIfied. The transition from the lCU 
to the operating room (OR) is a crucial period and 
the donor is continuously monitored, ventilated, and 
treated. . 
Intraoperative care of the donor is essentially simi-
lar to that of other critically ill patients undergoing 
major surgery, although management of pathoplw-
siologic changes unique to the donor should be 
clearly understood. In genera\, equipment and medi-
cations routineh' a\'ailable for general anesthesia are 
satisfactory for the management of donors. Howev-
er, a volume ventilator may be needed for donors re-
quiring high levels of PEEP or airway pressure. The 
operating room should be kept warm, and a warm-
ing blanket and blood warmer are necessary to pre-
vent hypothermia. A large volume of crystalloids, 
some colloid solutions (e.g., 5% albumin, plasma 
protein fraction, or hetastarch), and 5 units of 
packed red blood cells should be prepared. The elec-
trocardiogram is monitored, preferably using lead 
V5, to detect arrhythmias or mvocardial ischemia, 
particularly in heart donors. Blm)d pressure is mon-
itored by an indwelling catheter in the radial arterY 
or brachial arten'. The femoral arterY cannulation is 
avoided because the aorta will be" cross-clamped. 
Central venous pressure monitoring is essential 
[85], and a pulmonary arterial catheter is useful in 
unstable donors. Two-dimensional transesophageal 
echocardiograph\' may be used to assess preload 
and cardiac contractility in unstable heart donors. 
Urine output and body' temperature are monitored, 
and all or some of the following laboratory tests 
may be needed: hemoglobin and hematocrit, arte-
rial blood gas tensions and acid-base state, serum 
electrolytes, ionized calcium, lactate, and blood glu-
cose level. 
General anesthetics are required to blunt the sym-
pathetic response that occurs during surgery [86]. 
This so-called "mass reflex" is caused by neurogenic 
vasoconstriction and stimulation of the adrenal me-
dulla by the spinal reflex arc, and manifests as tachy-
cardia hypertension, perspiration, and involuntary 
movements. These movements, also known as "La-
zarus sign" (that includes arm and hand movements 
towards the body), can be very disturbing to those 
involved in the organ recovery, and muscle relaxants 
should be administered ahead of time. 
lsoflurane is the agent of choice because the de-
gree of myocardial depression is less than with other 
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inhalation agents. Halothane is avoided in liver dp-
nors because hepatotoxicit\' may be a concern in tlw 
presence of potential hepatic is·chemia. Enflurane is 
,l\'oided in kidney donors because it incre,lses the 
blood level of in()rganic fluoride. Slwrhlcting nar-
cotics such as Pentanvl (5-W ,ug/kg) Ill,l\' be used in 
hemodvnamicallv unstable donors. III ,lddition, 
muscle' relaxants 'pancuronillm bromide (0.0::; to O. I 
mg/kg) (lr vecuronium bromide (0.0::; to 0.1 mg/kg) 
are required to provide satist,lct(lrV abdomin,d mus-
cle relaxation and to abolish involuntary move-
ments. Other pharmacological interventions include 
systemic heparinization (300-500 U/kg) before can-
nulation of the aorta, mannitol (0.25 to 0.5 g/kg) and 
furosemide (40 mg) to induce diuresis before divi-
sion of the renal pedicle, and prevent ischemia-
induced acute tubular necrosis [R7-R9]. Alpha-adre-
nergic receptor blockers, such as phenoxybenzamine 
lwdrochloride, may be used to promote renal vaso-
dilation and prevent vasospasm [90]. However, these 
blockers are not recommended in multiple-organ 
procurement because their effects on other organs 
are unknown. Prophylactic administration of anti-
biotics such as broad-spectrum cephalosporins is 
recommended by some centers [91-(2), although its 
efficacv is controversial [45, 93]. 
In hypothermic donors, a mild respiratory alkalo-
sis (pH 7.4 to 7.5) may be preferred to improve tis-
sue perfusion [94, 95]. This goal is frequently 
achieved by ventilating with a tidal volume of 10 to 
15 mLlkg, a respiratory rate of fewer than 20 
breaths per minute, FlO:: of 30'},;, to 40%, and a low 
level of PEEP «5 cm H::O). However, when pulmo-
nary complications interfere with gas exchange the 
tidal volume is increased up to 20 mLlkg, the respi-
ratory rate up to 20 breaths per minute, and the 
PEEP up to 10 cm H::O. 
The goal of circulatory care is to preserve perfu-
sion of all organs that are to be procured bv main-
taining systolic blood pressure between 100 and 120 
mmHg, with a CVP less than 10 cm H::O and mini-
mal vasopressor support [49, 74, 96], Hypotension 
(systolic blood pressure <80 mmHg or mean arte-
rial pressure <40 mmHg) is associated with an in-
creased incidence of acute tubular necrosis and 
nonfunction of the donor kidneys [75, 77], as well 
as poor function of the liver [76]. However, main-
taining a satisfactory blood pressure is difficult to 
achieve at times because of altered circulatory phys-
iology in the brain dead donors. Preload frequently 
is decreased because of blood loss, vasomotor paral-
ysis, diuretic therapy, or diabetes insipidus. Tachy-
cardia, bradycardia, and arrhvthmias caused bv 
massive sympathetic discharg~ are not unusual, 
and myocardial contractility is frequently impaired 
by myocytolysis, coronary spasm, and redllCI1tln of 
myocardial energy storage [97]. Afterload may be 
increased by excessive sympathetic tone or de-
creased by vasomotor paralysis. 
Intravascular volume is adjusted with the guid-
ance of the CVP « 10 cm HoG). Fluid deficit is cor-
rected with the infusion of a balanced electrolyte so-
lution (e.g. lactated Ringer's) or a colloid solution 
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Recovery Data 
Surgeons Renal 
HepatIC 
Cardiac: 
HearVLung: 
Pancreas: 
Coordinators/Technicians (Tissue): 
/.R. Manno, H.R. Doy/e, C. Scotti-Fog/len/. TE. Star::/ 
Donor 10# 
Asslstlng: ________________ _ 
In O.R. ____ ;~ Incision ____ ;~ Depart O.R. (0) ____ ;~ Depart O.R. (T) ____ : 
Condition During Surgery (include: Blood Pressure, Urine Output, Complications, 
Comments) 
Operating Room Drugs (include dosage and time) 
Methypredmsolone: ____ _ Mannitol: _______ _ Furosemide: ________ _ 
Hepa"n: _______ _ Vasodilator: Blood Products _______ _ 
Antiblotics: _______ _ Others: ______________________ _ 
Nephrectomy Data Hepatectomy Data Cardiectomy Data 
En Bloc: YIN In Situ: YIN Precool Start _______ InfUSion Start: _____ _ 
Flush Sol'n: ______ Vol. Sol'nNol: ________ Sol'nNo!. _______ _ 
Final Flush (Sol'n VOl): ______ _ Portal Flush Start: _____ Ciampa Off: ______ _ 
Storage Sol'n: ________ _ 
Art Clamp: 
Flush Start 
Flush End: 
Warm Ischemia Time 
Clamps Off: 
R 
Cold Ischemia Time __ _ 
Single or Double Lung Data 
Sol'nNol: ________ Cold Ischemia Time 
Aortic Flush Start: D;e~e:::a:"r:D;t:;iD:D:u:::n:::g:"":D;a:a~t=a======= 
Sol'nNol: ________ Infusion Start (R) ____ _ 
Final Flush (Sol'nNol) ____ SoI'nVol: _______ _ 
Clamps Off: _______ Infusion Start (L) ____ _ 
Cold Ischemia Time _____ SoI'nNol: _______ _ 
Anatomy: ________ Clamps Off: ______ _ 
Cold Ischemia Time ___ _ 
Pancreas Data 
Infusion Start: ___________ _ Infusion Start: _____________ _ 
Sol'nNol. _____________ _ Sol'nNo!. ______________ _ 
Clamps Off: ____________ _ Final Flush; (Sol'nNol) ___________ _ 
Cold Ischemia Time _________ _ Clamps Off: ______________ _ 
Cold Ischemia Time 
Anatomy ______________ _ 
Renal Anatomy 
o 
Blops~D Results· _______________________________ _ 
Organs and Tissues Recovered (Check appropriate box and Circle "T" for Transplant, "R" lor Research) 
o R·KI TIR 0 L·KI TIR 0 LI TIR 0 LU TIR 0 PA T/R 0 HR TIR 0 HV TIA 0 MV T/A 0 Bones T/A 
o 8M T/R 0 Veins T/A 0 Skin TIA 0 Cornea T/A DINT T/A 0 Other T/A 
Fig. 4,3, Intraoperative data collection sheet used by the Western Pennsylvania Organ Procurement Organization, CORE (Cen· 
ter for Organ Recovery and Education). (Courtesy of Mr. Brian Broznick) (from [19]). 
(5% albumin or hetastarch) [98], Urine output and 
insensible losses are replaced by a hypotonic solu-
tion with glucose (e,g. 5% dextrose in 0.45% NaCl, 1 
mLlkg per hour), Adjustment of intravascular vol-
ume may decrease the need for vasopressors in 
many cases [991, but acute volume expansion may 
increase myocardial oxygen consumption, conges-
tive heart failure, arrhvthmias, and the need for in-
otropic support, because the compliance of the heart 
is decreased in most donors [77]. 
Severe cases of tachycardia and hypertension 
caused bv the mass ret lex mav be controlled bv the 
administration of general ane~stheticsI a beta-antag-
onist, such as labetalol hydrochloride or esmolol hy-
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drochloride, or a calcium channel blocker, such as 
verapamil hydrochloride [64]. Occasionally, an al-
pha-blocker such as hydralazine or sodium nitro-
prusside may be given to reduce afterload. Supra-
ventricular or ventricular arrhvthmias are treated 
with conventional antiarrhythmk drugs. Circulatory 
arrest, which occurs in llD~o of potential donors and 
in 66'X, of referred donors [72], is treated according 
to conventional circulaton' resuscitative measures, 
but if bradvcardia is a concern, a direct-acting agent 
such as isoproterenol or epinephrine is used be-
cause, as mentioned before, donors are unrespon-
sive to centrally-acting chronotropic drugs, such as 
atropine. 
Progressive hypothermia which is seen in up to 
86'!0 of donors because of the loss of hypothalamic 
function [49] which results in sinus bradycardia, 
atrioventricular dissociation, and ventricular ar-
rhvthmias. At a temperature lower than 28"C, pro-
IOllged PR and QT intervals and wide QRS complex-
es are replaced by T-wave inversion, ST-segment de-
pression, and rise of ventricuL:lr fibrillation. Other ef-
fects of hypothermia are a leftward shift in the he-
moglobin-oxygen dissociation curve, an increase in 
blood viscosity, decrease in splanchnic blood flow 
and glomerular filtration, hyperglycemia, and me-
tabolic and respiratorv acidosis. Body temperature is 
kept within the normal range (>35"C) by increasing 
the room temperature, infusing all fluids through a 
blood warmer, and using a warming blanket and a 
heated humidifier in the inspiratory limb of the ven-
tilation circuit. 
Adequate diuresis (>0.5 mLlkg per hour, prefer-
ably 1 to 1.5 mLlkg per hour) is important because 
urine output is an indirect indication of preload and 
is a prognostic indicator for renal and liver graft 
function [73]. The administration of fluid or dopa-
mine may be effective in maintaining adequate renal 
perfusion and diuresis. However, a high dose of do-
pamine (> 10 JIg/kg/min) may lead to acute tubular 
necrosis and nonfunction of the renal graft [75]. For 
persistent oliguria, furosemide (1-2 mg/kg) and man-
nitol (0.5 g/kg) may be administered. 
Metabolic acidosis caused by inadequate tissue 
perfusion may be compounded by respiratory acido-
sis. Because of potential myocardial depression, me-
tabolic acidosis is corrected by administration of so-
dium bicarbonate. 
When hypernatremia is a concern, tromethamine 
(tris-hvdroxvmethvlaminomethane, THAM) may be 
used (0.3 molar THAM [mL] = body weight [kg] x 
base deficit [,umollL]) instead of sodium bicarbonate. 
Electrolyte imbalances (hypernatremia, hypokale-
mia, hypocalcemia, hypophosphatemia, and hypo-
magnesemia) caused by fluid shifts and diabetes in-
sipidus may result in arrhythmias and myocardial 
dysfunction. Hypernatremia and hypokalemia are 
treated by administration of a hyponatremic solution 
(0.45% NaCl) and KCl (20 ,umollL). Ionized hypocal-
cemia caused by large blood transfusions is correct-
ed by the administration of calcium chloride or calci-
um gluconate to preserve cardiac contractility. Hy-
pomagnesemia is treated with magnesium sulfate 
31 
(50 mg/kg), also to preserve nwocardial contractility 
[100]. Glucose metabolism is relativel\' well main-
tained, although hypergl:'cemia may occur as the re-
sult of a decreased level of insulin and as a complica-
tion of diabetes insipidus. 
Once cardioplegia is induced, no further support-
ive care is necessary. After cross-clamping of the aor-
ta (the time is recorded by the procurement coor-
dinator - see Fig. 4.3) mechanical ventilation and 
monitoring are discontinued, and all cannulas are re-
moved. 
The organs are svviftly removed in the follm\'ing 
sequence: heart, lungs, liver, pancreas, intestine, 
and kidneys. No supportive care is needed for pro-
curement of corneas or bones because these tissues 
tolerate a prolonged ischemia without significant 
injury. 
DONOR OPERATION 
Before starting a multiorgan procurement it is 
mandatorv that the different surgical teams discuss 
the techniques and sequence they want to adopt. 
A detailed discussion of the surgical procedure is 
critical because, after aortic cross-clamping, time is 
of the essence. Everything should proceed as 
smoothly and expeditiously as possible, to mini-
mize organ damage. The basic principle of any do-
nor operation is the core cooling of the organs to 
be removed. Cooling of a solid organ at the time of 
donor circulatory arrest was described for experi-
mental liver transplantation 34 years ago [101]. It 
\'vas then promptly applied to/kidney preservation 
in clinical transplantation [102], and it still repre-
sents the single most important aspect of any or-
gan preservation technique. The first solution used 
was chilled Ringer's lactate, replaced in the late 
1960' s bv the so-called Collins solution, character-
ized by 'an electrolyte composition close to the in-
tracellular one [103]. This solution was successfullv 
used for about 20 vears, until the introduction of 
the University of 'Wisconsin solution [lO-1, 105], 
which extended the duration of organ viability. The 
easiest way to achieve almost immediate internal 
core cooling of the donor organs is by ill sitll in-
fusion of the preservation solution, chilled to 4"C, 
at the time of the circulatory arrest. The remaining 
technical aspects of organ retrieval are secondary 
to this critical maneuver. 
The technical details of the donor operation are 
provided in Chapter 5, and will not be repeated 
here. We will only stress a few points we believe to 
be important. 
Mediastinal dissection is carried out removing the 
lungs and heart en bloc if the block is to be used for a 
heart-lung transplant. The more common situation is 
one where the heart is harvested by one group and 
lungs are to be used for separate transplants. In this 
situation, once the cardioplegia and lung perfusion 
has been completed, the heart is carefully dissected 
by the two teams ensuring that enough pulmonary 
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Fig. 4.4. En-bloc harvesting of 1Iver and small bowel from a 
pediatric donor (from [19]). 
artery and left atrial cuff remain on both the heart 
and the lungs making them both available for trans-
plantation. Once the heart has been removed, the 
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lung team Gill then proceed ,",'ith extraction of the 
lungs. 
During this phase the abdominal organs are un-
touched, while they are exsanguinated and the cold 
perfusion is continued. Following the removal of the 
thoracic organs, the abdominal team proceeds with 
the final dissection and removal of the liver, pan-
creas, intestine, and kidneys. The technical steps 
have been outlined elsewhere bv us [40, 106-109) and 
others [110-112). After the organ recovery long seg-
ments of the iliac arteries and veins, inferior vena ca-
va and aorta [113) (and carotid arteries in children) 
should always be removed and stored under hy-
pothermic conditions. This ensures the ability to 
deal with all possible vascular problems that might 
be encountered during the recipient operations [113-
117]. 
With the development of the intestinal and multi-
visceral transplant program at the University of 
Pittsburgh (see Chapter 24), a technique was devel-
oped for the removal of essentially the entire abdom-
inal visceral bloc (Fig. 4.4) [48]. Anatomical consid-
erations are fundamental during intestinal and mul-
tivisceral procurement, because recipients require 
different types of intestinal transplantation (isolated 
small bowel, liver and small bowel, true multiviscer-
ai, etc.) based on different pathology and needs. 
These procurement techniques do not interfere with 
that of other organs, In our first 35 intestinal donor 
operations there were 62 kidneys, 35 livers, 18 hearts 
and 3 lungs procured simultaneously [48}. 
At the end of the operation the procurement coor-
dinator completes the form shown in Figure 5.3. 
These data are of critical importance for the recipient 
operations, and subsequent follow-up of the trans-
planted patients, which are the endpoint of a suc-
cessful multiple organ procurement. 
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